EP2662094A1 — Cylodextrin Complexation Methods for Formulating Peptide Proteasome Inhibitors
Assigned to Onyx Therapeutics Inc · Expires 2013-11-13 · 13y expired
What this patent protects
This disclosure provides methods for formulating compositions comprising one or more peptide proteasome inhibitors, in particular carfilzomib, and a cyclodextrin, particularly a substituted cyclodextrin. Such methods substantially increase the solubility and stability of these pr…
USPTO Abstract
This disclosure provides methods for formulating compositions comprising one or more peptide proteasome inhibitors, in particular carfilzomib, and a cyclodextrin, particularly a substituted cyclodextrin. Such methods substantially increase the solubility and stability of these proteasome inhibitors and facilitate both their manufacture and administration.
Drugs covered by this patent
- Kyprolis (carfilzomib) · Amgen
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.